A Phase 3, Randomized, Double-blind, Placebo controlled, Parrallel, Fixed Dose Study to Assess the Efficacy, Safety and Tolerability of NBI 98854 for the treatment of Tardive Dyskinesia

Administered By

Awarded By

Contributors

Start/End

  • November 1, 2014 - November 9, 2015